What is LOPJLB’s current signal on PLX?

LOPJLB’s latest quantitative signal on Protalix BioTherapeutics, Inc. (PLX) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is PLX in?

Protalix BioTherapeutics, Inc. (PLX) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Protalix BioTherapeutics, Inc. (PLX) do?

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also…

Where is Protalix BioTherapeutics, Inc. based / listed?

Protalix BioTherapeutics, Inc. is based in US, listed on AMEX.

Protalix BioTherapeutics, Inc. (PLX)

Healthcare · Biotechnology · AMEX · US

$2.41+1.26%Close

SELLRECOVERY · day 3

[SCORES & PROFILE]

FUND: 42
VALUE: 44
GROWTH: 72
GARP: 16
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC19.0%

REV YoY-

ROE31.6%

EPS YoY-

ROA17.2%

GROSS

NET

[VALUATION]

P/E TTM10.02

P/E FWD49.69

SECTOR PE22.62

INDUSTRY PE17.13

P/B2.71

P/FCF-

EV/EBITDA6.71

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E12.89

ALTMAN Z-

CURR RATIO2.94

ND/EBITDA-

BETA0.01

Protalix BioTherapeutics, Inc. (PLX)

Key stats

Sector peers

Industry peers

Prediction markets

FUNDAMENTALS

Company news